XTNT News & Events

Reports Q1 revenue $20.9M vs. $32.9M last year. Sean Browne, President and CEO of Xtant Medical, stated, "The Q1 of 2026 and subsequent period were pivotal for Xtant. Proceeds from the Companion Spine transaction allowed us to strengthen our balance sheet while the HEMOBLAST Bellows distribution agreement announced in April expanded our addressable market into the multi-billion-dollar hemostatics category. We are particularly encouraged by the potential commercial synergies to be realized following the integration of Dilon's 21-person field sales force into our own organization, positioning us to drive topline growth and margin expansion this year and beyond. These developments, together with recent product launches, position us to best serve the needs of surgeons and patients alike with our comprehensive biologics product portfolio."

Revenue guidance increase reflects the recently announced exclusive license agreement with Dilon Technologies and anticipated incremental revenue contribution from Dilon's HEMOBLAST Bellows.

Xtant Medical Holdings and Dilon Technologies announced that the companies have entered into an agreement whereby Xtant has acquired exclusive U.S. distribution rights to Dilon's Hemoblast Bellows for high-performance hemostasis following certain surgical procedures. Xtant plans to update its full-year 2026 financial guidance in light of the new distribution arrangement in connection with the release of its first quarter 2026 financial results.